SMi Source Lesson Alzheimer's Disease: Therapeutic Approaches

  • SMi Source lesson Alzheimer's Disease: Therapeutic Approaches has the following microlearning topics

    • 1. Learning Objectives

    2. New Pharmacological Therapy for AD Disease Modification

    3. Overview: AD Progression - Characteristics and Goals

    4. Overview: AD Progression - Aβ Peptide Accumulation

    5. The Cascade

    6. Why Does A beta Accumulate?

    7. Amyloid Precursor Protein (APP)

    8. APP Processing

    9. Amyloid Hypothesis

    10. γ-Secretase

    11. Neurotoxicity: Aβ Oligomers and Aβ Plaques

    12. Change in the Equilibrium of Aβ

    13. Effects on Notch Signaling

    14. Development of Inhibitors

    15. GSI-953 and GSI-953: Effects in Transgenic Mice and Aβ Levels

    16. GSI-953: Single Oral Dose in Humans

    17. MK-0752: Phase I Trials

    18. BMS-708163 Preclinical Data: Rapid and Sustained Reduction

    19. BMS-708163 Preclinical Data: Aβ40 Reduction

    20. β-Secretase Inhibition

    21. CTS-21166: Small-Molecule β-secretase Inhibitor

    22. Knowledge Check: Enzymes or Protein Fragments

    23. Knowledge Check: Secretase of Compound Targets

    24. Overview: Aβ Immunotherapy

    25. Biologics

    26. Active Immunization - Vaccination

    27. Passive Immunization

    28. Potential Mechanisms for Aβ Clearance

    29. Animal Studies: First Immunization Evidence

    30. Animal Studies: Immunization and Disease Severity

    31. AN1792 Phase I Safety Trial

    32. AN1792 Phase IIa Trial

    33. AN1792 Immune Response

    34. AN1792 Autopsy Findings

    35. AN1792 Cognitive Findings

    36. AN1792 CSF Findings

    37. AN1792 MRI Measures

    38. Lessons Learned from AN1792

    39. CAD106: Preclinical Results

    40. CAD106: Phase I

    41. CAD106: Phase II

    42. V950: Active Anti-Aβ Vaccine

    43. Overview: Passive Immunization

    44. Animal Studies

    45. Bapineuzumab Phase II: Cognitive Measures

    46. Bapineuzumab Phase II

    47. Bapineuzumab Phase III

    48. Ponezumab

    49. Solanezumab: Preclinical Studies and Rationale

    50. Solanezumab: First Human Clinical Study

    51. Solanezumab: Phase II Trial - Examination

    52. Solanezumab: Phase II Trial - Conclusion

    53. Solanezumab Phase III

    54. Intravenous Immunoglobulin (IVIg) Pilot Studies

    55. Intravenous Immunoglobulin (IVIg) Phase II Results

    56. Knowledge Checks: Autoimmune Encephalitis

    57. Knowledge Check: Agents and Emerging Therapies